Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
OLIG2 Gene Supports Notion of Myelin Abnormalities in Schizophrenia

4 August 2006. Reduced expression of genes involved with myelination and myelinating oligodendrocytes is a widely observed phenomenon in schizophrenia. Imaging and morphological studies also point to problems with myelination and oligodendrocytes in the disease. By homing in on genes involved in this process, Michael O’Donovan, Mike Owen, and colleagues at Cardiff University in the United Kingdom and in New York have identified a new potential susceptibility gene for schizophrenia. The gene, OLIG2 (oligodendrocyte lineage transcription factor 2), is a master regulator of oligodendrocyte differentiation and function. SNP association studies suggest that OLIG2 alleles confer risk for schizophrenia by themselves, as well as in interaction with other myelin-related genes. Evidence for a functional relationship between the interacting genes involved in oligodendrocyte function was also found from gene expression studies suggesting coordinated expression. The study is set to appear in PNAS online today.

Several oligodendrocyte/myelination-related genes have previously been implicated in schizophrenia. Recently, the Cardiff group showed that a low-expressing allele of the mature oligodendrocyte marker CNP (2’3’-cyclic nucleotide 3’phosphodiesterase) gene is linked to schizophrenia (see SRF related news story). But the lower expression of CNP and several other genes observed in schizophrenia could be a downstream effect of other genetic variations or environmental factors. In the current report, first author Lyudmila Georgieva and colleagues selected the OLIG2 transcription factor as a candidate gene which could affect the expression of many other oligodendrocyte genes. They applied several independent methods to ask whether OLIG2 variants influence susceptibility to schizophrenia.

In the first analysis, the researchers genotyped nine known markers across the OLIG2 gene in pooled DNA from cases and controls and then in individuals, resulting in two SNPs that were significantly linked to disease. A second analysis screened DNA from people with schizophrenia for new polymorphisms, and revealed additional associated SNPs. Individual genotyping of between 600 and 700 cases and controls yielded three SNPs that were strongly associated with disease.

If altered oligodendrocyte function or myelination were critical to the risk of schizophrenia, the researchers reasoned, they might see interactions between OLIG2 and CNP variants, and that is exactly what they observed. They also tested for interaction with two other risk genes, those for neuregulin-1 (NRG1) and its receptor ErbB4. While no interaction was detected for NRG1 and OLIG2, there was a significant interaction with ErbB4, although it was not as strong as that seen for CNP.

To take another measure of functional links between the oligodendrocyte genes, the researchers looked for coexpression of mRNAs in brain tissue. There, the expression data correlations followed their genetic data precisely. From gene chip experiments, they found a strong positive correlation of OLIG2 and CNP expression in several brain regions. One of two probes for ErbB4 message showed a negative correlation with OLIG2 expression, but there was no correlation of OLIG2 with NRG1. Using mouse brain tissue, they found evidence of linkage between OLIG2 expression and the CNP locus, and vice versa, suggesting that the genes may be mutually regulating each other.

“The data presented here provide a coherent and strong statistical case for the hypothesis that OLIG2 is a susceptibility gene for schizophrenia, but the mechanistic influences to be drawn are yet unclear,” the authors write. Also unclear is the identity of the functional allele or alleles of OLIG2 that confer the main risk and the interaction with CNP. But by their approach of combining multiple analyses, the authors put the legs under a sturdy platform to support their stated hypothesis that OLIG2 is an important “host gene” for variants that affect schizophrenia risk by affecting a whole network of oligodendrocyte/myelin-associated genes.—Pat McCaffrey.

Reference:
Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L, Holmans P, MacGregor S, Zammit S, Wilkinson J, Williams H, Nikolov I, Williams N, Ivanov D, Davis KL, Haroutunian V, Buxbaum JD, Craddock N, Kirov G, Owen MJ, O’Donovan MC. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci U S A. 2006 Aug 4; [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
Comment by:  William Honer
Submitted 4 August 2006 Posted 4 August 2006

This paper demonstrates several important shifts in research strategies for schizophrenia. Many previous studies of candidate genes in the illness have chosen their targets based on concepts of the mechanism of action of antipsychotic drugs, or by virtue of the proximity of a gene to a genetic linkage site defined with anonymous markers. The choice of candidate gene here is based on a wide range of neurobiological evidence, including studies of gene expression and protein levels. As well, the authors do not limit their study to one gene; instead, they expand their investigation to include plausibly interacting gene targets. Analysis of complex disorders will likely need more than simple models, and the approach here is worth noting.

The gap still remains between the DNA-mRNA approaches and protein analysis. Gene expression is one factor determining mRNA levels. However, especially in human brain tissue samples, many other antemortem and postmortem factors contribute to the measured level of mRNA. The meaning of gene expression measures obtained for...  Read more


View all comments by William Honer

Comment by:  Patricia Estani
Submitted 22 August 2006 Posted 23 August 2006
  I recommend the Primary Papers
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright